Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Africa

- PMLiVE

Eli Lilly’s Jaypirca recommended by CHMP to treat chronic lymphocytic leukaemia

Approximately 100,000 new cases of the disease are diagnosed globally every year

- PMLiVE

Eli Lilly unveils plans to invest $27bn in four new US manufacturing sites

The investment raises the company’s total US capital expansion commitments to more than $50bn since 2020

- PMLiVE

Eli Lilly and OliX partner to advance early-stage metabolic disease candidate

Metabolic-associated steatohepatitis is expected to affect over 19 million adults in the US by 2039

- PMLiVE

Eli Lilly shares two-year results for Omvoh in active Crohn’s disease patients

Inflammatory bowel disease affects almost one in every 100 people in the US

- PMLiVE

Eli Lilly’s Omvoh granted FDA approval to treat Crohn’s disease in adults

The drug is already approved in the US to treat ulcerative colitis, another form of inflammatory bowel disease

- PMLiVE

Eli Lilly to acquire Scorpion’s solid tumour programme in deal worth $2.5bn

STX-478 is in phase 1/2 development for breast cancer and other advanced solid tumours

- PMLiVE

Eli Lilly and Alchemab Therapeutics partner to develop new ALS therapies

The neurodegenerative disease affects approximately 30,000 people in the US

- PMLiVE

Eli Lilly’s Omvoh recommended by CHMP to treat Crohn’s disease in adults

The drug is already approved in the EU to treat ulcerative colitis, another form of inflammatory bowel disease

- PMLiVE

Eli Lilly announces $3bn expansion to US injectables manufacturing facility

The investment will help Lilly meeting the growing demand for its diabetes and obesity medicines

- PMLiVE

Sanofi unveils plans to build €1bn insulin production base in China

The site will focus on serving the insulin medication needs of local diabetic patients

- PMLiVE

Eli Lilly shares positive results for modified titration of Alzheimer’s drug donanemab

The neurodegenerative disorder accounts for up to 75% of the 982,000 dementia cases in the UK

- PMLiVE

Eli Lilly’s Alzheimer’s drug Kisunla approved by MHRA but not recommended by NICE

The health technology assessment agency said that more evidence is needed on the clinical and cost-effectiveness of the drug

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links